La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference
February 04 2015 - 08:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that George F.
Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will
provide a corporate overview at the 17th Annual BIO CEO &
Investor Conference taking place February 9-10 in New York
City.
17th Annual BIO CEO
& Investor Conference Presentation Details
Date: Monday, February 9, 2015 Time: 5:30 pm Eastern
Time Location: Louis XVI Room @ The Waldorf Astoria New York
Webcast:
LJPC Webcast Link
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
four product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension and hepatorenal
syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor
for the potential treatment of chronic kidney disease. LJPC-1010,
La Jolla’s second-generation galectin-3 inhibitor, is a more potent
and purified derivative of GCS-100 that can be delivered orally for
the potential treatment of nonalcoholic steatohepatitis and other
diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s
novel formulation of hepcidin for the potential treatment of iron
overload. For more information on La Jolla, please visit
www.ljpc.com.
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive Officer(858)
207-4264gtidmarsh@ljpc.comorChester S. Zygmont, IIISenior Director
of Finance(858) 207-4262czygmont@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Feb 2024 to Mar 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2023 to Mar 2024